01.06.2015 14:46:23
|
Merck And Dynavax Collaborate On Immuno-Oncology Therapies - Quick Facts
(RTTNews) - Merck & Co. Inc. (MRK) and Dynavax Technologies Corp. (DVAX) announced that they have entered into two clinical trial collaboration agreements to investigate the potential synergistic effect of combining immunotherapies from both companies' pipelines: Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), and its investigational anti-interleukin-10 (anti-IL-10) immunomodulator, MK-1966, with Dynavax's investigational toll-like receptor 9 (TLR9) agonist, SD-101.
As per the terms of the agreement, Dynavax will sponsor and fund the SD-101 and KEYTRUDA study. Merck will sponsor and fund the SD-101 and MK-1966 study. The agreements include provisions where the parties may agree to extend either collaboration to include a Phase 3 clinical trial. Additional details of the agreements between Dynavax and Merck, through a subsidiary, were not disclosed.
SD-101, KEYTRUDA, and MK-1966 are immunotherapies designed to enhance the body's own defenses in fighting cancer. SD-101 is designed to mediate anti-tumor effects by triggering both innate and adaptive immune responses, including the induction of high levels of Type 1 interferon to stimulate recruitment of T-cells.
KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 (programmed death receptor-1) and its ligands, PD-L1 and PD-L2. MK-1966 is an investigational anti-IL-10 immunomodulator designed to neutralize the immune-suppressive environment for tumors.
The collaboration includes multiple studies that will evaluate: Safety and efficacy of combining SD-101 with KEYTRUDAin patients with advanced melanoma; this Phase 1b/2, multicenter, open-label study is expected to be initiated in the second half of 2015; Safety and efficacy of combining SD-101 with MK-1966 in patients with solid or hematological malignancies; this Phase 1 study is expected to be initiated in the second half of 2015.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Merck Co.mehr Nachrichten
19.02.25 |
Handel in New York: Dow Jones gibt nach (finanzen.at) | |
19.02.25 |
NYSE-Handel Dow Jones am Mittwochmittag leichter (finanzen.at) | |
18.02.25 |
Zurückhaltung in New York: Dow Jones verliert (finanzen.at) | |
18.02.25 |
Dow Jones 30 Industrial-Titel Merck-Aktie: So viel Verlust hätte ein Investment in Merck von vor einem Jahr bedeutet (finanzen.at) | |
14.02.25 |
Minuszeichen in New York: Dow Jones schlussendlich leichter (finanzen.at) | |
14.02.25 |
Verluste in New York: Dow Jones präsentiert sich am Nachmittag schwächer (finanzen.at) | |
14.02.25 |
Freitagshandel in New York: Dow Jones verliert mittags (finanzen.at) | |
13.02.25 |
Handel in New York: Dow Jones beendet den Donnerstagshandel mit Gewinnen (finanzen.at) |
Analysen zu Merck Co.mehr Analysen
Aktien in diesem Artikel
Merck Co. | 81,60 | 0,25% |
|